Genentech’s New NMOSD Drug Offers At-Home Treatment, Lower Cost
List price is below competitors from Alexion, Viela Bio
Enspryng (satralizumab) is the third FDA-approved drug but only at-home treatment for neuromyelitis optica spectrum disorder; significant percentage of patients are not being treated.
